UpFront Diagnostics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
UpFront Diagnostics General Information
Description
Developer of a blood testing device designed to identify large vessel occlusion strokes at the point of care. The company offers a CE-marked test that uses blood biomarkers from a single drop of blood to detect severe strokes in emergency settings, enabling clinicians, paramedics, and nurses to make timely diagnosis and treatment decisions.
Contact Information
Website
upfrontdiagnostics.comCorporate Office
- Li Ka Shing Centre
- Robinson Way
- Cambridge CB2 0RE
- England, United Kingdom
Corporate Office
- Li Ka Shing Centre
- Robinson Way
- Cambridge CB2 0RE
- England, United Kingdom
UpFront Diagnostics Timeline
UpFront Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 10. Later Stage VC | 15-May-2025 | Completed | Clinical Trials - General | |||
| 9. Seed Round | 27-Jun-2023 | Completed | Generating Revenue | |||
| 8. Grant | 27-Jun-2023 | Completed | Generating Revenue | |||
| 7. Seed Round | 01-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Jan-2022 | Completed | Clinical Trials - Phase 2 | |||
| 5. Angel (individual) | 06-Feb-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 01-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Seed Round | 01-Jan-2019 | $260K | $260K | Completed | Clinical Trials - Phase 2 | |
| 2. Grant | 01-Dec-2018 | $1.29M | Completed | Clinical Trials - Phase 2 |
UpFront Diagnostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 1,467 | $0.001327 | $36.19 | $36.19 | 1x | $36.19 | 0.56% | |
| Ordinary | 2,000 | $0.001327 | $12.29 | $12.29 | 1x | $12.29 | 0.77% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
UpFront Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
UpFront Diagnostics Patents
UpFront Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202407291-D0 | D-dimer, gial fibrillary acidic protein (gfap) osteoprotegerin (opg) and osteopontin (opn) as biomarkers for stroke cause by large vessel occlusion | Active | 17-Apr-2020 | ||
| GB-2627388-A | D-dimer, gial fibrillary acidic protein (gfap) osteoprotegerin (opg) and osteopontin (opn) as biomarkers for stroke caused by large vessel occlusion | Active | 17-Apr-2020 | ||
| GB-202200967-D0 | D-dimer, glial fibrillary acidic protein (gfap) osteoprotegerin (opg) and osteopontin (opn) as biomarkers for stroke caused by large vessel occlusion | Active | 17-Apr-2020 | ||
| GB-2600844-A | D-dimer, glial fibrillary acidic protein (gfap) osteoprotegerin (opg) and osteopontin (opn) as biomarkers for stroke caused by large vessel occlusion | Active | 17-Apr-2020 | ||
| GB-2627388-A8 | D-dimer, glial fibrillary acidic protein (gfap) osteoprotegerin (opg) and osteopontin (opn) as biomarkers for stroke caused by large vessel occlusion | Active | 17-Apr-2020 | G01N33/6896 |
UpFront Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
UpFront Diagnostics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Phoenix Sustainable Investments | Infrastructure | Minority | ||
| SBRI Healthcare | Government | |||
| APEX Ventures | Venture Capital | Minority | ||
| Creator Fund | Venture Capital | Minority | ||
| PanaceaStars | Accelerator/Incubator | Minority |
UpFront Diagnostics FAQs
-
When was UpFront Diagnostics founded?
UpFront Diagnostics was founded in 2017.
-
Where is UpFront Diagnostics headquartered?
UpFront Diagnostics is headquartered in Cambridge, United Kingdom.
-
What is the size of UpFront Diagnostics?
UpFront Diagnostics has 7 total employees.
-
What industry is UpFront Diagnostics in?
UpFront Diagnostics’s primary industry is Diagnostic Equipment.
-
Is UpFront Diagnostics a private or public company?
UpFront Diagnostics is a Private company.
-
What is UpFront Diagnostics’s current revenue?
The current revenue for UpFront Diagnostics is .
-
How much funding has UpFront Diagnostics raised over time?
UpFront Diagnostics has raised $7.09M.
-
Who are UpFront Diagnostics’s investors?
Phoenix Sustainable Investments, SBRI Healthcare, APEX Ventures, Creator Fund, and PanaceaStars are 5 of 9 investors who have invested in UpFront Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
